Bioactivation of benzylic and allylic alcohols via sulfo-conjugation

Chemico-Biological Interactions

Volumn 109, Issue 1-3, 1998, Pages 221-235

  Surh, Young Joon ^a  

^a Seoul National University   (South Korea)

Author keywords

Allylic alcohols; Benzylic alcohols; Bioactivation; Carcinogenicity and mutagenity; Sulfotransferase; Sulfuric acid esters

Indexed keywords

ADENOSINE 3' PHOSPHATE 5' PHOSPHOSULFATE; ALLYL COMPOUND; BENZO[A]PYRENE DERIVATIVE; BENZYL ALCOHOL DERIVATIVE; CARCINOGEN; MUTAGENIC AGENT; POLYCYCLIC AROMATIC HYDROCARBON; SULFATE; SULFOTRANSFERASE;

BIOTRANSFORMATION; CONFERENCE PAPER; CONJUGATION; DNA BINDING; ENZYME ACTIVITY; ESTERIFICATION; MOUSE; NONHUMAN; RAT; SULFATION;

ALLYL COMPOUNDS; ANIMALS; BENZYL ALCOHOLS; BIOTRANSFORMATION; HUMANS; SULFOTRANSFERASES; SULFURIC ACIDS;

EID: 0032548978     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(97)00134-8     Document Type: Conference Paper

References (71)

1. Miller J.A. Sulfonation in chemical carcinogenesis. Chem.-Biol. Interact. 92:1994;329-341.
2. Coughtrie M.W.H. Sulphation catalyzed by the human cytosolic sulphotransferases - chemical defense or molecular terrorism? Hum. Exp. Toxicol. 15:1996;547-555.
3. Flesher J.W., Kadry A.M., Chien M., Stansbury K.H., Gairola C., Sydnor K.L. Metabolic activation of carcinogenic hydrocarbons in the meso-position (L-region). Cooke M., Dennis A.J. Polynuclear Aromatic Hydrocarbons: Formation, Metabolism and Measurement. 1983;505-515 Battell Press, Columbus, OH.
4. Cavalieri E.L., Roth R.W., Rogan E.G. Hydroxylation and conjugation at the benzylic carbon atom: A possible mechanism of carcinogenic activation for some methyl-substituted aromatic hydrocarbons. Jones P.W., Leber P. Polynuclear Aromatic Hydrocarbons. 1979;517-529 Ann Arbor publishers, Ann Arbor, MI.
5. Flesher J.W., Tay L.K. Reactions of the carcinogens 7-hydroxymethyl-12-methylbenz[a]anthracene and 7-acetoxymethyl-12-methylbenz[a]anthracene with DNA. Res. Commun. Chem. Pathol. Pharmacol. 22:1978;345-355.
6. Tay L.K., Sydnor K.L., Flesher J.W. Binding of 6-hydroxymethylbenzo[a]pyrene and 6-acetoxymethylbenzo[a]pyrene to DNA. Chem.-Biol. Interact. 25:1979;35-44.
7. Fried J. One-electron oxidation of polycyclic aromatics as a model for the metabolic activation of carcinogenic hydrocarbons. Ts'o P.O.P., DiPalo J.A. Chemical Carcinogenesis (Part I). 1974;197-215 Marcel Dekker, New York.
8. Watabe T., Ishizuka T., Isobe M., Ozawa N. A 7-hydroxymethyl sulfate ester as an active metabolite of 7,12-dimethylbenz[a]anthracene. Science. 215:1982;403-405.
9. Watabe T., Hakamata Y., Hiratsuka A., Ogura K. A 7-hydroxymethyl sulfate ester as an active metabolite of the carcinogen, 7-hydroxymethylbenz[a]anthracene. Carcinogenesis. 7:1986;207-214.
10. Watabe T., Hiratsuka A., Ogura K. Sulfotransferase-mediated covalent binding of the carcinogen 7,12-dihydroxymethylbenz[a]anthracene to calf thymus DNA and its inhibition by glutathione transferase. Carcinogenesis. 8:1987;445-453.
11. Okuda H., Hiratsuka A., Nojima H., Watabe T. A hydroxymethyl sulphate ester as an active metabolite of the carcinogen, 5-hydroxymethylchrysene. Biochem. Pharmacol. 35:1986;535-538.
12. Watabe T., Ogura K., Okuda H., Hiratsuka A. Hydroxymethyl sulfate esters as reactive metabolites of the carcinogen, 7-methyl- and 7,12-dimethylbenz[a]anthracene and 5-methylchrysene. Kato R., Estabrook R.W., Cayen M.N. Xenobiotic Metabolism and Disposition. 1989;393-400 Taylor and Francis, London.
13. Bayless J.H., Jablonski J.E., Roach S.M., Sullivan P.D. Inhibition of the mutagenicity and metabolism of 6-methylbenzo[a]pyrene and 6-hydroxymethylbenzo[a]pyrene. Biochem. Pharmacol. 35:1986;2313-2322.
14. Surh Y.-J., Liem A., Miller E.C., Miller J.A. Metabolic activation of the carcinogen 6-hydroxymethylbenzo[a]pyrene: Formation of an electrophilic sulfuric acid ester and benzylic DNA adducts in rat liver in vivo and in reactions in vitro. Carcinogenesis. 10:1989;1519-1528.
15. Surh Y.-J., Liem A., Miller E.C., Miller J.A. The strong hepatocarcinogenicity of the elctrophilic and mutagenic metabolite 6-sulfooxymethylbenzo[a]pyrene and its formation of benzylic DNA adducts in the livers of infant male B6C3F1 mice. Biochem. Biophys. Res. Commun. 172:1990;85-91.
16. Surh Y.-J., Blomquist J.C., Liem A., Miller J.A. Metabolic activation of 9-hydroxymethyl-10-methylanthracene and 1-hydroxymethylpyrene to electrophilic, mutagenic, and tumorigenic sulfuric acid esters by rat hepatic sulfotransferase activity. Carcinogenesis. 11:1990;1451-1460.
17. Glatt H., Henschler R., Phillips D.H., Blake J.W., Steinberg P., Seidel A., Oesch F. Sulfotransferase-mediated chlorination of 1-hydroxymethylpyrene to a mutagen capable of penetrating indicator cells. Environ. Health Perspect. 88:1990;43-48.
18. Glatt H., Pauly K., Frank H., Seidel A., Oesch F., Harvey R.G., Werle-Schneider G. Substance-dependent sex differences in the activation of benzylic alcohols to mutagens by hepatic sulfotransferases of the rat. Carcinogenesis. 15:1994;2605-2611.
19. Glatt H. Bioactivation of mutagens via sulfation. FASEB J. 11:1997;314-321.
20. Surh Y.-J., Liem A., Lai C.-C., Miller J.A., Miller E.C. Hepatic DNA and RNA adduct formation from 7-hydroxymethyl-12-methylbenz[a]anthracene and its electrophilic sulfuric acid ester metabolite in preweanling rats and mice. Biochem. Biophys. Res. Commun. 144:1987;576-582.
21. Surh Y.-J., Liem A., Miller E.C., Miller J.A. Age- and sex-related differences in activation of the carcinogen 7-hydroxymethyl-12-methylbenz[a]anthracene to an electyrophilic sulfuric acid ester metabolite in rats: possible involvement of hydroxysteroid sulfotransferase activity. Biochem. Pharmacol. 41:1991;213-221.
22. Monnerjahan S., Seidel A., Steinberg P., Oesch F., Hinz M., Stezowsky J.J., Hewer A., Phillips D.H., Glatt H.R. Formation of DNA adducts from 1-hydroxymethylpyrene in liver cells in vivo and in vitro. Phillips D.H., Castegnaro M., Bartsch H. Postlabelling Methods for Detection of DNA adducts, International Agency for Research on Cancer, Lyon, France. 1983;431-445.
23. Ogura K., Sohotome T., Sugiyama A., Okuda H., Hiratsuka A., Watabe T. Rat liver cytosolic hydroxysteroid sulfotransferase (sulfotransferase a) catalyzing the formation of reactive sulfate esters from carcinogenic polycyclic hydroxymethylarenes. Mol. Pharmacol. 37:1990;848-854.
24. Ogura K., Kajita J., Narihata H., Watabe T., Ozawa S., Nagata K., Yamazoe Y., Kato R. Cloning and sequencing of a rat liver cDNA encoding hydroxysteroid sulfotransferase. Biochem. Biophys. Res. Commun. 165:1989;168-174.
25. C.N. Falany, J. Wheeler, L. Coward, D. Keehan, J.L. Falany, S. Barnes, Bioactivation of 7-hydroxymethyl-12-methylbenz[a]anthracene by rat liver bile acid sulfotransferase I, J. Biochem. Toxicol. (1992) 241-248.
26. Glatt H., Seidel A., Harvey R.G., Coughtrie M.W.H. Activation of benzylic alcohols to mutagens by human hepatic sulphotransferases. Mutagenesis. 9:1994;553-557.
27. Glatt H., Pauly K., Czich A., Falany J.L., Falany C.N. Activation of benzylic alcohols to mutagens by rat and human sulfotransferases expressed in Escherichia coli. Eur. J. Pharmacol. 293:1995;173-181.
28. Glatt H., Pauly K., Piee-Staffa A., Seidel A., Hornhardt S., Czich A. Activation of promutagens by endogenous and heterologous sulfotransferases expressed in continuous cell cultures. Toxicol. Lett. 72:1994;13-21.
29. Czich A., Bartsch I., Dogra S., Hornhardt S., Glatt H.R. Stable heterologous expression of hydroxysteroid sulphotransferase in Chinese hamster V79 cells and their use for toxicological investigations. Chem.-Biol. Interact. 92:1994;119-128.
30. Glatt H., Christoph S., Czich A., Pauly K., Schwierzok A., Seidel A., Coughtrie M.W.H., Doehmer J., Falany C.N., Phillips D.H., Yamzoe Y., Bartsch I. Rat and human sulfotransferases expressed in Ames's Salmonella typhimurium strains and Chinese hamster V79 cells for the activation of mutagens. Hengstler J.G., Oesch F. Control Mechanisms of Carcinogenesis. 1996;99-115 Druckerei Thieme, Meissen, Germany.
31. Glatt H., Werle-Schneider G., Enders N., Monnerjahan S., Pudil J., Czich A., Seidel A., Schwarz M. 1-Hydroxymethylpyrene and its sulfuric acid ester: Toxicological effects in vitro and in vivo, and metabolic aspects. Chem.-Biol. Interact. 92:1994;305-319.
32. Cho Y.S., Kim B.-Y., Lee S.-T., Surh Y.-J., Chung A.-S. Chemopreventive effect of chlorophyllin on mutagenicity and cytotoxicity of 6-sulfooxymethylbenzo[a]pyrene. Cancer Lett. 107:1996;223-228.
33. Surh Y.-J. Sulfotransferase-mediated activation of some benzylic and allylic alcohols. Snyder R. et al. Biological Reactive Intermediates V. 1996;339-345 Plenum, New York.
34. Surh Y.-J., Kwon H., Tannenbaum S.R. Sulfotransferase-mediated activation of 4-hydroxy- and 3,4-dihydroxy-3,4-dihydrocyclopenta[c,d]pyrene, major metabolites of cyclopenta[c,d]pyrene. Cancer Res. 53:1993;1017-1022.
35. Surh Y.-J., Tannenbaum S.R. Bioactivation of cyclopenta- and cyclohexa-fused polycyclic aromatic hydrocarbons via the formation of benzylic sulfuric acid esters. Polycyclic Aromat. Compd. 7:1994;83-90.
36. Jeong H.-K., Shlyankevich M., Surh Y.-J. Intrinsic mutagenicity and electrophilicity of 1-sulfooxy-3-methylcholanthrene: Implications for metabolic activation of the carcinogen 3-methylcholanthrene. Biochem. Mol. Biol. Int. 37:1995;877-883.
37. Surh Y.-J., Tannenbaum S.R. Sulfotransferase-mediated activation of 7,8,9,10-tetrahydro-7-ol, 7,8-dihydrodiol, 7,8,9,10-tetraol derivatives of benzo[a]pyrene. Chem. Res. Toxicol. 8:1995;693-698.
38. Glatt H., Henschler R., Frank H., Seidel A., Yang C., Abu-Shqara E., Harvey R.G. Sulfotransferase-mediated mutagenicity of 1-hydroxymethylpyrene and 4H-cyclopenta[def]chrysen-4-ol and its enhancement by chloride ion. Carcinogenesis. 14:1993;599-602.
39. Archer S., Pica-Mattoccia L., Cioli D., Seyed-Mozaffari A., Zayed A.-H. Preparation and antischistosomal and antitumor activity of hycanthone and some of its congeners. Evidence for the mode of action of hycanthone. J. Med. Chem. 31:1988;254-260.
40. Hartman P.E. Early years of the Salmonella mutagen tester strains: Lessons from hycanthone. Environ. Mol. Mutagen. 16:1989;39-45.
41. Haese W.H., Bueding E. Long-term hepatocellular effects of hycanthone and of two other antischistosomal drugs in mice infected with Schistosoma mansoni. J. Pharmacol. Exp. Ther. 197:1976;703-713.
42. Hartman P.E., Hulbert P.B. Genetic activity spectra of some antischistosomal compounds, with particular emphasis on thioxanthenones and benzothiopyranoindazoles. J. Toxicol. Environ. Health. 1:1975;243-270.
43. Cioli D., Pica-Mattoccia L., Rosenberg S., Archer S. Evidence for the mode of antischistosomal action of hycanthone. Life Sci. 37:1985;161-171.
44. Howe R. Carcinogenicity of 'alderlin' (pronethalol) in mice. Nature. 207:1965;594-595.
45. Black J.W., Crowther A.F., Shanks R.G., Smith L.H., Dornhurst A.C. A new adrenergic beta-receptor antagonist. Lancet. i:1964;1080-1081.
46. Bicker U., Fischer W. Enzymatic aziridine synthesis from β aminoalcohols - a new example of endogenous carcinogen formation. Nature. 249:1974;344-345.
47. Breuer H., Knuppen R., Haupt M. Metabolism of oestrone and oestradiol-17β in human liver in vitro. Nature. 212:1966;76.
48. Takagi H., Komatsu K.-I., Yoshizawa I. Synthesis and mechanism of hydrolysis of estrogen 6-sulfates: model compounds for demonstrating the carcinogenesis of estrogen. Steroids. 56:1991;173-179.
49. Lutz D., Eder E., Neudecker T., Henschler D. Structure-mutagenicity relationship in α,β-unsaturated carbonyl compounds and their corresponding allylic alcohols. Mutat. Res. 93:1982;305-315.
50. Eder E., Henschler D., Neudecker T. Mutagenic properties of allylic and α,β-unsaturated compounds: Consideration of alkylating mechanisms. Xenobiotica. 12:1982;831-848.
51. Kaye C.M. Biosynthesis of mercapturic acids from allyl alcohol, allyl esters and acrolein. Biochem. J. 134:1973;1093-1101.
52. Mauron J. The Maillard reaction in food; a critical review from the nutritional standpoint. Prog. Food Nutr. 5:1981;5-35.
53. Ulbricht R.J., Northup S.J., Thomas J.A. A review of 5-hydroxymethylfurfural (HMF) in parentheral solutions. Fund. Appl. Toxicol. 4:1984;843-853.
54. Zhang X.-M., Chan C.C., Stamp D., Minkin S., Archer M.C., Bruce W.R. Initiation and promotion of colonic aberrant crypt foci in rats by 5-hydroxymethyl-2-furaldehyde in thermolyzed sucrose. Carcinogenesis. 14:1993;773-775.
55. Lee Y.-C., Schlyankevich M., Jeong H.-K., Douglas J.S., Surh Y.-J. Bioactivation of 5-hydroxymethyl-2-furaldehyde to an electrophilic and mutagenic allylic sulfuric acid ester. Biochem. Biophys. Res. Commun. 209:1995;996-1002.
56. Surh Y.-J., Tannenbaum S.R. Activation of the Maillard reaction product 5-(hydroxymethyl)furfural to strong mutagens via allylic sulfonation and chlorination. Chem. Res. Toxicol. 7:1994;313-318.
57. Surh Y.-J., Liem A., Miller J.A., Tannenbaum S.R. 5-Sulfooxymethylfurfural as a possible ultimate mutagenic and carcinogenic metabolite of the Maillard reaction product, 5-hydroxymethylfurfural. Carcinogenesis. 15:1994;2375-2377.
58. Jordan V.C. A current view of tamoxifen for the treatment and prevention of breast cancer. Br. J. Pharmacol. 110:1993;507-517.
59. Wiseman H. Tamoxifen: New membrane-mediated mechanisms of action and therapeutic advances. Trends Pharmacol. Sci. 15:1994;83-89.
60. King C.M. Tamoxifen and the induction of cancer. Carcinogenesis. 16:1995;1449-1454.
61. Styles J.A., Davies A., Lim C.K., De Matteis F., Stanley L.A., White I.N.H., Yuan Z.-X., Smith L.L. Genotoxicity of tamoxifen, tamoxifen epoxide and toremifen in human lymphoblastoid cells containing human cytochrome P-450s. Carcinogenesis. 15:1994;5-9.
62. D.H. Phillips, A. Hewer, I.N.H. White, P.B. Farmer, Co-chromatography of a tamoxifen epoxide-deoxyguanosine acid adduct with a major DNA adduct formed in the livers of tamoxifen-treated rats, Carcinogenesis (1994) 793-795.
63. Phillips D.H., Carmichael P.L., Hewer A., Cole K.J., Poon G.K. Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res. 54:1994;5518-5522.
64. Potter G.A., McCague R., Jarman M. A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis. 15:1994;439-442.
65. Randerath K., Bi J., Mabon N., Sriram P., Moorthy B. Strong intensification of mouse hepatic tamoxifen DNA adduct formation by pretreatment with the sulfotransferase inhibitor and ubiquitous environmental pollutant pentachlorophenol. Carcinogenesis. 15:1994;797-800.
66. Topinka J., Andrae U., Schwarz L.R., Wolff T. Cyproterone acetate generates DNA adducts in rat liver and in primary rat hepatocyte cultures. Carcinogenesis. 14:1993;423-427.
67. Werner S., Topinka J., Wolff T., Schwarz L.R. Accumulation and persistence of DNA adducts of the synthetic steroid cyproterone acetate in rat liver. Carcinogenesis. 16:1995;2369-2372.
68. Kerdar R.S., Baumann A., Brudny-Kloppel M., Biere H., Blode H., Kuhnz W. Identification of 3α-hydroxy-cyproterone acetate as a metabolite of cyproterone acetate in the bile of female rats and the potential of this and other already known or putative metabolites to form DNA adducts in vitro. Carcinogenesis. 16:1995;1835-1841.
69. Zhang K., Tang C., Rashed M., Cui D., Tombret F., Botte H., Lepage F., Levy R.H., Baillie T.A. Metabolic chiral inversion of stiripentol in the rat. I. Mechanistic studies. Drug Metab. Dispos. 22:1994;545-553.
70. Tang C., Zhang K., Lepage F., Levy R.H., Baillie T.A. Metabolic chiral inversion of stiripentol in the rat. II. Influence of route of administration. Drug Metab. Dispos. 22:1994;554-560.
71. Boddy A.V., Zhang K., Lepage F., Tombret F., Slatter J. G., Baillie T.A., Levy R.H. In vitro and in vivo investigations of dihydropyridine-based chemical delivery systems for anticonvulsants. Pharm. Res. 8:1991;690-697.